128 related articles for article (PubMed ID: 37311357)
21. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
[TBL] [Abstract][Full Text] [Related]
22. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U; Tsourti Z; Vervita K; Peters S
Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
[TBL] [Abstract][Full Text] [Related]
23. Monitoring PD-L1 Expression on Circulating Tumor-Associated Cells in Recurrent Metastatic Non-Small-Cell Lung Carcinoma Predicts Response to Immunotherapy With Radiation Therapy.
Moran JA; Adams DL; Edelman MJ; Lopez P; He J; Qiao Y; Xu T; Liao Z; Gardner KP; Tang CM; Lin SH
JCO Precis Oncol; 2022 Dec; 6():e2200457. PubMed ID: 36516370
[TBL] [Abstract][Full Text] [Related]
24. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials.
Shi Y; Duan J; Guan Q; Xue P; Zheng Y
Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922
[TBL] [Abstract][Full Text] [Related]
25. The relative and absolute benefit of programmed death receptor-1 vs programmed death ligand 1 therapy in advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Yi K; Zhu Q; Kuang YK; Jiang SC; Hu H
Int Immunopharmacol; 2020 Oct; 87():106852. PubMed ID: 32759049
[TBL] [Abstract][Full Text] [Related]
26. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
[TBL] [Abstract][Full Text] [Related]
27. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer.
Zhao S; Gao G; Li W; Li X; Zhao C; Jiang T; Jia Y; He Y; Li A; Su C; Ren S; Chen X; Zhou C
Lung Cancer; 2019 Apr; 130():10-17. PubMed ID: 30885328
[TBL] [Abstract][Full Text] [Related]
28. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
29. The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials.
Liu Q; Fang Z; Liu M; Xu R; Yi F; Wei Y; Zeng L; Zhang W
J Clin Pharm Ther; 2021 Dec; 46(6):1519-1530. PubMed ID: 34101874
[TBL] [Abstract][Full Text] [Related]
30. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials.
Pathak R; De Lima Lopes G; Yu H; Aryal MR; Ji W; Frumento KS; Wallis CJD; Klaassen Z; Park HS; Goldberg SB
Cancer; 2021 Mar; 127(5):709-719. PubMed ID: 33119177
[TBL] [Abstract][Full Text] [Related]
31. Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC.
Takeyasu Y; Yoshida T; Shibaki R; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Yamamoto N; Motoi N; Ohe Y
Clin Lung Cancer; 2021 Mar; 22(2):127-133.e3. PubMed ID: 33183972
[TBL] [Abstract][Full Text] [Related]
32. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
33. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
34. Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
Toral KJ; Wuenschel MA; Black EP
PLoS One; 2021; 16(8):e0256416. PubMed ID: 34437586
[TBL] [Abstract][Full Text] [Related]
35. Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50.
Gainor JF; Rizvi H; Jimenez Aguilar E; Skoulidis F; Yeap BY; Naidoo J; Khosrowjerdi S; Mooradian M; Lydon C; Illei P; Zhang J; Peterson R; Ricciuti B; Nishino M; Zhang J; Roth JA; Grishman J; Anderson D; Little BP; Carter BW; Arbour K; Sauter JL; Mino-Kenudson M; Heymach JV; Digumarthy S; Shaw AT; Awad MM; Hellmann MD
Ann Oncol; 2020 Mar; 31(3):404-411. PubMed ID: 32067682
[TBL] [Abstract][Full Text] [Related]
36. Immune checkpoint inhibitors alone vs immune checkpoint inhibitors-combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis.
Wang Y; Han H; Zhang F; Lv T; Zhan P; Ye M; Song Y; Liu H
Br J Cancer; 2022 Sep; 127(5):948-956. PubMed ID: 35641819
[TBL] [Abstract][Full Text] [Related]
37. Clinical and molecular characteristics associated with survival among cancer patients receiving first-line anti-PD-1/PD-L1-based therapies.
Zhou Y; Wang C; Jiang Y; Ren P; Shao J; Tuersun P; Li W
Biomarkers; 2020 Sep; 25(6):441-448. PubMed ID: 32744106
[TBL] [Abstract][Full Text] [Related]
38. Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study.
Lang D; Huemer F; Rinnerthaler G; Horner A; Wass R; Brehm E; Akbari K; Granitz M; Hutarew G; Kaiser B; Greil R; Lamprecht B
Target Oncol; 2019 Dec; 14(6):707-717. PubMed ID: 31654203
[TBL] [Abstract][Full Text] [Related]
39. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
Rizvi H; Sanchez-Vega F; La K; Chatila W; Jonsson P; Halpenny D; Plodkowski A; Long N; Sauter JL; Rekhtman N; Hollmann T; Schalper KA; Gainor JF; Shen R; Ni A; Arbour KC; Merghoub T; Wolchok J; Snyder A; Chaft JE; Kris MG; Rudin CM; Socci ND; Berger MF; Taylor BS; Zehir A; Solit DB; Arcila ME; Ladanyi M; Riely GJ; Schultz N; Hellmann MD
J Clin Oncol; 2018 Mar; 36(7):633-641. PubMed ID: 29337640
[TBL] [Abstract][Full Text] [Related]
40. The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort.
Nielsen TJ; Varga MG; Cronister CT; Ring BZ; Seitz RS; Ross DT; Schweitzer BL; McGregor K
Cancer Immunol Immunother; 2023 Jul; 72(7):2075-2086. PubMed ID: 36806983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
